Community Protocol
Dihexa
Laboratory DMSO stock-solution examples, aliquot conversion, community-reported patterns and important limitations.
Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.
Scope
Laboratory DMSO stock-solution examples, aliquot conversion, community-reported patterns and important limitations.
Available strengths: 10 MG
Stock note: This protocol source marks the compound as laboratory-stock-only for preparation context.
Preparation Examples
Laboratory stock-solution examples only. DMSO volumes and aliquots shown below are not syringe units, a route of administration, or human dosing instructions.
| Setup | Diluent | Concentration | Unit conversion |
|---|---|---|---|
| 10 MG vial – 2 mL example | Dissolve in 2 mL DMSO | 5 mg/mL | Each 1 uL aliquot = 5 mcg |
| 10 MG vial – 1 mL example | Dissolve in 1 mL DMSO | 10 mg/mL | Each 1 uL aliquot = 10 mcg |
Syringe Conversion
| Reported amount | 10 MG setup | 10 MG setup |
|---|---|---|
| 1 mg | 200 uL | 100 uL |
| 2.5 mg | 500 uL | 250 uL |
| 5 mg | 1000 uL | 500 uL |
| 10 mg | 2000 uL | 1000 uL |
Recalculate from the actual mass and final solvent volume. Use calibrated laboratory pipettes; never inject a DMSO stock solution.
Community-Reported Patterns
| Recurring report | Frequency seen | Context in reports |
|---|---|---|
| 2-5 mg | Once daily | Lower-start reports |
| 5-10 mg | Once daily | Most recurring range |
| 10-20 mg | Daily in some reports | Higher experimental use |
Observations
- Community discussions most often centered on memory, focus and cognitive-performance goals.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.
Caveats
- DMSO stock solutions are for analytical or in-vitro laboratory use only and must not be injected.
- Dihexa lacks established human safety and dosing data; theoretical growth-signalling concerns remain unresolved.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.